A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

PURPOSE: Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen. MATERIALS AND METHODS: Eligibility included histologically c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Tak, Kim, Heung Tae, Han, Ji-Youn, Yoon, Sung Jin, Kim, Hyae Young, Nam, Byung-Ho, Lee, Jin Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843756/
https://www.ncbi.nlm.nih.gov/pubmed/26044164
http://dx.doi.org/10.4143/crt.2015.061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843756/
https://www.ncbi.nlm.nih.gov/pubmed/26044164
http://dx.doi.org/10.4143/crt.2015.061

Ejemplares similares